Year: 2021

PHILADELPHIA, PA, Nov. 18, 2021 (GLOBE NEWSWIRE) — FTAC Zeus Acquisition Corp. (NASDAQ:ZINGU) (the “Company”), a blank-check company led by Daniel G. Cohen as Chairman of the Board and Ryan M. Gilbert as President and Chief Executive Officer formed for the purpose of acquiring or merging with one or more technology and financial services technology companies, today announced the pricing of its upsized initial public offering of 35,000,000 units at a price of $10.00 per unit, for gross proceeds to the Company of $350,000,000. The Company’s units will be listed on the Nasdaq Global Market under the symbol “ZINGU” and will begin trading on November 19, 2021. Each unit issued in the offering consists of one share of Class A common stock of the Company and one-half of one warrant, each whole warrant exercisable for...

Contributing to improved performance of inverter modules in electric vehiclesUAES-ROHM Form Power Solution SiC PartnershipMr. Guo Xiaolu (right), Deputy General Manager, UAES, and Mr. Raita Fujimura (left), Chairman, ROHM Semiconductor (Shanghai) Co., Ltd.Santa Clara, CA and Kyoto, Japan, Nov. 18, 2021 (GLOBE NEWSWIRE) — ROHM Semiconductor today announced that the company has been certified as a preferred supplier of SiC power solutions by United Automotive Electronic Systems Co., Ltd., (UAES), a Chinese Tier 1 comprehensive automotive manufacturer. ROHM and UAES have been collaborating and carrying out detailed technical exchanges on the development of automotive applications utilizing SiC power devices since 2015. In 2020, ROHM established a joint SiC technology laboratory at UAES headquarters (Shanghai, China)...

–– 58 of the original 59 subjects continue in the open-label extension portion of the Phase 2 trial. –– Phase 3 data for TransCon PTH expected in Q1 2022. COPENHAGEN, Denmark, Nov. 18, 2021 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), today announced top-line results from Week 84 of the Company’s Phase 2 PaTH Forward Trial, a global trial evaluating the safety, tolerability, and efficacy of its investigational TransCon PTH product candidate in adult patients with hypoparathyroidism (HP). TransCon PTH is an investigational once-daily prodrug of parathyroid hormone (PTH) designed to restore physiologic levels of PTH 24 hours a day. The week 84 data showed that subjects treated with TransCon PTH had both mean serum calcium levels and urinary calcium excretion that remained stable and in the normal range and that most subjects...

VANCOUVER, British Columbia, Nov. 18, 2021 (GLOBE NEWSWIRE) — Xali Gold Corp. (TSXV:XGC) (“Xali Gold” and/or the “Company”) is pleased to announce that the Company has agreed to terms for a Services Contract (“Contract”) with Windfall Geotek Inc. (TSX-V: WIN, OTCQB: WINKF, FSE: L7C2) for them to use their digital exploration technology tools to assist Xali Gold in delineating potential drill targets on the Victoria Property in Newfoundland.  Windfall Geotek’s Artificial Intelligence (“AI”) targeting technology analyzes all geological data to generate the highest probability targets and has been successful in assisting in many gold discoveries in Canada and elsewhere internationally. Windfall Geotek’s AI targeting technology has contributed to gold discoveries on numerous projects, in several areas including: Lebel Gold Project,...

$IBGR – DRYWORLD Online Shop Drops – Announcing the Launch of D’s Online StoreCoreD Pro CollectionNEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) — DRYWORLD Brands, Inc. (OTC Pink: IBGR) is pleased to announce the launch of the online store today November 18th.  Global Fulfilment Is Our Commitment Today is the day! The long awaited and eagerly anticipated opening of DRYWORLD’s online store is here. Everybody knows that e-commerce is the fastest growing segment of the retail market in Europe, North America and Asia. Research suggests 20% of US retail sales are made online while 25% of retail sales in the UK are online, forecasting growth to 34.5% by 2023. China is the clear market leader with 44.8% of all retail sales online in 2020, forecasted to increase to 52.1% of retail sales by the end of 2021. It’s clear...

Lille, France; Cambridge, MA; November 18, 2021 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, is proud to announce that NIS4® technology’s utility has been recognized in a Stage 1 study1 undertaken by the Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE) initiative of the Foundation for the National Institutes of Health’s Biomarkers Consortium as demonstrating a unique performance in identifying patients with “at-risk” Non-Alcoholic Steatohepatitis (NASH). The late-breaking oral presentation “LO1: PRIMARY RESULTS OF THE NIMBLE STAGE 1-NASH CRN STUDY OF CIRCULATING BIOMARKERS FOR NONALCOHOLIC STEATOHEPATITIS AND ITS ACTIVITY AND FIBROSIS STAGE” at The Liver Meeting 2021 highlighted the importance for the...

Columbus, OH, Nov. 18, 2021 (GLOBE NEWSWIRE) — Mettler-Toledo International Inc. (NYSE:MTD) today announced the webcast of its presentation at the virtual Evercore ISI 4th Annual HealthCONx Conference on Thursday, December 2, 2021, at 11:20 a.m. Eastern Time.  To hear a live webcast of the presentation, visit the investor relations page on the Company’s Web site at www.mt.com/investors.  A replay of the webcast will be available for seven days. METTLER TOLEDO (NYSE: MTD) is a leading global supplier of precision instruments and services. We have strong leadership positions in all of our businesses and believe we hold global number-one market positions in most of them. We are recognized as an innovation leader and our solutions are critical in key R&D, quality control, and manufacturing processes for customers in a wide...

A new Stanford study published in Cell Host and Microbe finds that protection against influenza infection may be achieved through mechanisms other than the development of serum antibodies STANFORD, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) — A new Stanford study published in Cell Host and Microbe has demonstrated that VXA-A1.1, an investigational oral tablet flu vaccine under development by Vaxart, Inc. (NASDAQ: VXRT), had cellular correlates of protection against influenza infection.1 These cellular correlates were found using mass cytometry analysis of vaccine-elicited cellular immune responses in the peripheral blood of participants in a previously reported Phase II H1N1 challenge study of VXA-A1.1.2 The U.S. Centers for Disease Control and Prevention (CDC) estimates that, on average, 36,000 people in the U.S. died from the flu...